3/4/2022 7:36:32 AM
Adamis Pharma Reveals Retirement Of Richard Williams, Effective April 15
10/18/2021 8:16:03 AM
Adamis Receives FDA Approval For ZIMHI For The Treatment Of Opioid Overdose
7/13/2021 8:19:38 AM
Adamis Urges Stockholders To Vote To Reelect The Company's Board Of Directors At Upcoming Annual Meeting On July 16
6/28/2021 7:10:07 AM
Adamis Urges Stockholders To Vote To Re-elect All Five Members Of Board
6/14/2021 9:10:19 AM
Adamis Urges Stockholders To Vote On WHITE Proxy Card To Re-elect All Five Members Of Board
6/11/2021 7:35:35 AM
Adamis Says Clinical Trial Start-up Activities Are Underway For Examining Effects Of Tempol
6/1/2021 7:42:54 AM
Adamis Provides Business Update; Says NDA For ZIMHI Submitted To FDA
5/17/2021 7:35:47 AM
Adamis Resubmits ZIMHI NDA To FDA For Treatment Of Opioid Overdose
4/12/2021 7:26:11 AM
Adamis Plans To Resubmit NDA For ZIMHI To FDA Within Next 45 Days
1/29/2021 9:10:06 AM
Adamis Prices Public Offering Of 40.54 Mln Shares Of Common Stock At $1.11/Shr
1/20/2021 9:01:33 AM
Adamis Announces IND Submission To FDA For Tempol For Treatment Of COVID-19